Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1014P - Resistance landscape to almonertinib in EGFR-mutated NSCLC

Date

10 Sep 2022

Session

Poster session 14

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

mi Tian

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

M. Tian1, Z. Lu2, S. Chen2, G. Lu2, F. Bu2, W. Deng2, R. Ding2

Author affiliations

  • 1 Department Of Respiratory And Critical Care Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 210008 - Nanjing/CN
  • 2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1014P

Background

Almonertinib is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with demonstrated activity against EGFR sensitizing mutations and EGFR T790M mutation. Despite the success of almonertinib, acquired resistance inevitably occurs.

Methods

To identify mechanisms of resistance to almonertinib and characterize clinically, we identified patients with EGFR-mutant lung cancers who had next-generation sequencing performed on tumor tissue or plasma after developing acquired resistance to almonertinib.

Results

1) We collected post-almonertinib samples from 79 patients, the majority were female (n = 54, 68.4%), median age was 64 (range 27-83). All patients had an EGFR activating mutation. 2) When almonertinib was given as initial treatment, EGFR-dependent mutations which may lead to the acquired resistance were identified in 23.1% (9/39) patients, including C797S (1 pts), L833V (2 pts), L747P (1 pts), E709V (1 pts), EGFR amplification(6 pts). Bypass or downstream activating mutations were detected in 38.5% (15/39) patients, including EML4-ALK rearrangement (1 pts), MET amplification (8 pts), KRAS mutations (2 pts), MYC amplification (3 pts), PIK3CA mutations (2 pts), CDK4 amplification (2 pts) and CDK6 amplification (2 pts). 3) When almonertinib was given as second-line treatment, EGFR-dependent mutations which may lead to the acquired resistance were identified in 32.5% (13/40) patients, including C797S (1 pts), V834L (2 pts), G724S (2 pts), V769L (1 pts), L718Q (1 pts), E709V (1 pts) and EGFR amplification (7 pts). Bypass or downstream activating mutations were detected were in 27.5% (11/40) patients, including MET amplification (5 pts), ERBB2 amplification (2 pts), MYC amplification (1 pts), CDK4 amplification (3 pts), CDK6 amplification (2 pts), CCNE1 amplification (1 pts), BRAF V600E (1 pts), KRAS mutations (1 pts) and PIK3CA mutations (3 pts).

Conclusions

Hence, the resistance landscape to almonertinib is similar to osimertinib, repeated tumor biopsies, as well as plasma genotyping at the time of progression on almonertinib, are crucial steps in unraveling resistance mechanisms and guiding future treatments.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.